Heat-stable ritonavir tablets: a new formulation of a pharmacokinetic enhancer for HIV. - Wikidata - awgldk - TriplyDB

Heat-stable ritonavir tablets: a new formulation of a pharmacokinetic enhancer for HIV.

Heat-stable ritonavir tablets: a new formulation of a pharmacokinetic enhancer for HIV.

http://www.wikidata.org/entity/Q37818237

about

Melt extrusion with poorly soluble drugs - An integrated review.

P2860

Q50161058-6545DBDE-5949-48CD-A951-387C0712E4BB

P2860

Heat-stable ritonavir tablets: a new formulation of a pharmacokinetic enhancer for HIV.

http://www.wikidata.org/entity/Q37818237

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 10 December 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Heat-stable ritonavir tablets: a new formulation of a pharmacokinetic enhancer for HIV.

@en

Heat-stable ritonavir tablets: a new formulation of a pharmacokinetic enhancer for HIV.

@nl

type

label

Heat-stable ritonavir tablets: a new formulation of a pharmacokinetic enhancer for HIV.

@en

Heat-stable ritonavir tablets: a new formulation of a pharmacokinetic enhancer for HIV.

@nl

prefLabel

Heat-stable ritonavir tablets: a new formulation of a pharmacokinetic enhancer for HIV.

@en

Heat-stable ritonavir tablets: a new formulation of a pharmacokinetic enhancer for HIV.

@nl

P1433

Q37818237-BC4970B5-8FB0-4BAD-BDC6-E396A770A6BA

P1476

Q37818237-1DB365AD-D7F0-4173-A31B-E6211FB3F207

P2093

Q37818237-3B9A6C6A-C30C-4A6D-8697-2CA9DBDD080B

P2860

Q37818237-06ABAE2D-C436-4080-ABD8-0089CAF7A3C0

Q37818237-4622F2DE-F83D-4C64-BA09-9CADCBDB755F

Q37818237-8F9E0C48-4241-405F-82BB-098637DD2A2F

Q37818237-8FEBF3C5-C779-4F03-BA95-70BF7FD56A9A

Q37818237-A3A6CC99-C26C-49AA-B9B9-3765EF822DAF

Q37818237-AEEE3E18-81F4-49CE-A9B4-6BDF5A02B540

Q37818237-AF9303CD-EE84-484D-B015-FB53C5F939A4

Q37818237-BF6F33C1-014F-4F65-A01C-DEE130A226AE

Q37818237-C0F60F73-1659-4948-8017-3970FCD4DDE5

Q37818237-F6E107E4-75F5-4855-ACB8-3570CE6CD886

P304

Q37818237-3A5DD2C1-36E3-422D-AE14-8474C8D05F88

P31

Q37818237-35aae6cd-ef48-41a7-8ce8-17aab97d9b2b

Q37818237-A87F4B73-B7BD-4004-B0DF-CD00777F57B5

P356

Q37818237-971F85B6-FD0C-4916-9ECD-9D03F83C9A66

P407

Q37818237-874FB5F3-EAFA-4268-8DC9-13578587E299

P433

Q37818237-76BA780F-C21D-4540-A1B8-20CFAA7E9794

P478

Q37818237-05E31A23-96A0-465B-BE56-E1D14F8A47BA

P50

Q37818237-1C472460-B3DE-4D33-961F-4FE94A667AB5

P577

Q37818237-ACC4BACF-CDDF-48B0-A570-43AC41192CFB

P698

Q37818237-AA0B900B-F895-4B79-AEA8-76203C0A4CB7

P356

14656566.2011.542151

P1433

Expert Opinion on Pharmacotherapy

P1476

Heat-stable ritonavir tablets: a new formulation of a pharmacokinetic enhancer for HIV

@en

P2093

Jennifer G Steinberg

http://www.w3.org/2001/XMLSchema#string

P2860

Drug interactions of HIV protease inhibitors.

Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection.

Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients.

Principles and practice of HIV-protease inhibitor pharmacoenhancement.

Significant improvements in self-reported gastrointestinal tolerability, quality of life, patient satisfaction, and adherence with lopinavir/ritonavir tablet formulation compared with soft gel capsules

Formulation preference, tolerability and quality of life assessment following a switch from lopinavir/ritonavir soft gel capsule to tablet in human immunodeficiency virus-infected patients.

Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV.

Formation of nano/micro-dispersions with improved dissolution properties upon dispersion of ritonavir melt extrudate in aqueous media.

Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity.

The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect.

P304

141-148

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14656566.2011.542151

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

Elizabeth M Sherman

P577

2010-12-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21142696

http://www.w3.org/2001/XMLSchema#string